Kiran Mazumdar Shaw

#BioE3 Policy for “Fostering High-Performance Biomanufacturing,” launched a year ago, has recorded “commendable” progress, with states being urged to set up BioE3 Cells as collaborative hubs for driving India’s bioeconomy says Dr Jitendra Singh Hon'ble Union Minister of State (IC) for Science and Technology. The Union Government will extend all support for the operationalisaiton of the these cells. Further, India’s transformation in the pharmaceutical sector underlines the potential of biotechnology as a growth engine. The initiatives undertaken in this new sector are embedding Biomanufacturing into India's economic and strategic framework and is contributing to the idea of Atmanirbhar Bharat.  Rajesh Gokhale MyGov India

338

5 Comments

Biocon will continue to deepen its push in the insulin business, even as it will have GLP-1 weight-loss therapy as one of the key focus areas in its future growth strategy — Shreehas Tambe chief executive of Biocon Biologics https://lnkd.in/gqjK54Hi

159

1 Comment

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝: Kiran Mazumdar Shaw, builder of India's leading biotech enterprise (Biocon) and a pioneer in the development of biologics and biosimilars, shares her story and learnings from business Watch the full interview: https://lnkd.in/g5-rwuCX Interviewed by Biotech CEO Sisterhood editorial board member Sheila Gujrathi, MD, Kiran Mazumdar-Shaw describes her beginnings in designing enzymes, and eventually pioneering biologics and biosimilars after an initial success in making recombinant human insulin for the India market. She discusses her emphasis on affordable innovation and shares business learnings from her career. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills | Genezen

86

8 Comments

💊 𝗢𝗻𝗲 𝗠𝗼𝗿𝗲 𝗮𝗻𝗱 𝗖𝗼𝘂𝗻𝘁𝗶𝗻𝗴: 𝗜𝗻𝗱𝗶𝗮’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗚𝗶𝗮𝗻𝘁𝘀 𝗞𝗲𝗲𝗽 𝗠𝗮𝗸𝗶𝗻𝗴 𝗚𝗹𝗼𝗯𝗮𝗹 𝗠𝗼𝘃𝗲𝘀 AUROBINDO PHARMA LTD is reportedly closing in on a $5.5 billion acquisition of Zentiva – #Europe’s leading generics player. If successful, this will be the largest-ever pharma buyout by an Indian company, surpassing even Sun Pharma’s landmark Ranbaxy deal. This isn’t just another M&A headline. It reflects a larger story of Indian healthcare scaling globally: 🌍 Expanding footprints in Europe & beyond 📈 Growing consolidation of pharmaceutical assets 💰 Indian pharma’s rising appetite for big-ticket global acquisitions 𝗙𝗿𝗼𝗺 #𝗕𝗶𝗼𝗰𝗼𝗻 𝘁𝗼 #𝗦𝘂𝗻𝗣𝗵𝗮𝗿𝗺𝗮 𝘁𝗼 #𝗖𝗶𝗽𝗹𝗮 – 𝗮𝗻𝗱 𝗻𝗼𝘄 𝗔𝘂𝗿𝗼𝗯𝗶𝗻𝗱𝗼 – 𝗜𝗻𝗱𝗶𝗮𝗻 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗮𝗿𝗲 𝗿𝗲𝘄𝗿𝗶𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝘂𝗹𝗲𝘀 𝗼𝗳 𝗴𝗹𝗼𝗯𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗹𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽. 🚀 The boom is real. And it’s only the beginning. #Healthcare #MergersAndAcquisitions #Pharma #IndiaGrowthStory #Aurobindo #India Opulix Advisory Services

53

Advancing CAR T Conversations in Central India! Immuneel recently hosted the CellSpectrum Esperenza – Nagpur Roundtable Meeting, uniting leading haemato-oncologists from Nagpur and Raipur, both in-person and virtually. The focused discussion centred on the clinical applications of CAR T cell therapy, addressing real-world challenges and opportunities in treating patients with limited conventional options. Through CellSpectrum Esperenza, we aim to: ·        Facilitate peer exchange on cutting-edge cell therapies ·        Bring real-world clinical strategies to the forefront ·        Strengthen our commitment to education and access in next-gen immuno-oncology Together, we are building an ecosystem ready for the future of cancer care. Tanmay Gharat Anil Kamat Dr Nishad Dhakate Rajat Bajaj Dr. Saurabh Prasad Dr Pankaj Dwivedi Dr. Avinash Pophali Avtar krishan Ganju Rahul Arora DIBYENDU DE vishvdeep khushoo #Immuneel #CellSpectrum #Esperenza #CART #Immunotherapy #HaematoOncology #CancerCare #Innovation #Access #OncologyLeadership

181

3 Comments

We were delighted to welcome the Mumbai Biocluster to NIBRT today, represented by Prof. Ratnesh Jain. Prof. Jain shared a compelling overview of the rapid evolution of India’s biopharma sector, highlighting its strategic role in the country’s ambition to be among the top three global economies by 2047, marking the centenary of India’s independence. Key insights from the session: - 70% of the world’s vaccines are manufactured in India. - Strong growth in biologics manufacturing, driven by biosimilars and CDMO/CRDMO activity. - A national focus on building indigenous originator companies supported by entrepreneurial regulatory and clinical trial systems. - Over 17,000 educational institutions and 50 million students – yet a significant demand for a skilled biopharma workforce. We look forward to deepening research and training collaborations between Ireland and India, fostering innovation and talent development across borders. Killian O'Driscoll John Milne PhD Julia Rakovets Darrin Morrissey Ratnesh Jain #Biopharma #GlobalCollaboration #India #Ireland #NIBRT #MumbaiBiocluster

194

6 Comments

The US move to impose a 100% tariff on imported branded medicines is a challenge, but also an opportunity. In my latest The Economic Times article, I share how this shift could strengthen India’s manufacturing backbone, accelerate self-reliance, and push innovation in biologics, biosimilars, and advanced drug delivery systems. Read here: https://lnkd.in/ghfdbssP #IndianPharma #USTariff #GlobalHealthcare #Innovation #AffordableHealthcare #Policy

741

23 Comments

Requesting 4 Candid Feedback : 💊 The Business of Conferences (India’s total CME market at ≈ $1.6 billion (~₹13,280 crore) in Indian – Boon, Bane, or Both? Dark Currency to White ? Every year, the Indian pharmaceutical industry spends crores of rupees sponsoring, organising, and attending high-profile doctor conferences — from ANCIPS, MediConclave, APICON, AIOC, PEDICON, IOACON, FOGSI Annual Conference, to CardioCon, DermaCon, and many more. What Really Happens at These Conferences? For Doctors 🩺 . Barring a few committed academicians who deliver lectures, present research papers, and share genuine scientific updates with slides, a large portion of attendees treat the event as… well… a networking getaway. . For many, it’s about meeting peers, exploring the exhibition stalls, and yes, enjoying the gala dinners, wines & cultural nights. . In between sessions, there’s often a mix of catching up with old friends and meeting new company representatives. For Senior Pharma Managers 👔 . Zonal, Regional, and National Heads attend to ensure their company’s visibility is maximised. . They meet key doctors, negotiate future business opportunities, and build relationships over coffee tables or banquet dinners. . Many also supervise the execution of sponsorship commitments — from ensuring the brand logo is visible on banners, to making sure the sponsored symposium runs as planned. For MRs, ASMs, and RSMs 🚶‍♂️ . Medical Representatives (MRs) usually manage stall activity, greet doctors, and distribute literature or samples. . Area Sales Managers (ASMs) coordinate the flow of visiting doctors, handle last-minute arrangements, and act as a bridge between field teams and the head office. . Regional Sales Managers (RSMs) often focus on higher-value relationship building — escorting key opinion leaders (KOLs) to sponsored events, facilitating introductions, and ensuring smooth logistics for VIP doctors. Pros of Conferences ✅ . Knowledge Sharing: Platform for genuine academic exchange (when it happens sincerely). . Relationship Building: Helps pharma teams strengthen trust with key doctors. . Brand Visibility: Strategic placements and sponsorships enhance recall. Networking: Facilitates doctor-to-doctor and doctor-to-pharma connections. Cons of Conferences ❌ . High Cost, Questionable ROI: Sponsorships run into lakhs or crores, but measurable returns are often vague. . Distraction from Core Purpose: Entertainment sometimes overshadows academic goals. . Overcrowded Branding: With dozens of companies vying for attention, differentiation is tough. . Fatigue Factor: Doctors & pharma teams attend multiple such events a year, reducing the novelty. The Bigger Question 🤔 💬 I’d love to hear from doctors, MRs, managers, and conference organisers — What’s your take on the real value of these conferences? #IndianPharma #PharmaMarketing #MedicalConferences #ANCIPS #APICON #FOGSI #CardioCon #Dermacon #PharmaIndustry #DoctorEngagement #PharmaSales #HealthcareMarketing

74

21 Comments